Skip to content
Biodatica
Start free

Investigator

Jorge Silvio Gutkind

UNIVERSITY OF CALIFORNIA, SAN DIEGO · funded by NCI, NIDCR

Companies
1

Resolved onto their grants.

Grants
8

Federal awards on file.

Non-dilutive funding
$4.3M

Summed across those awards.

First award
Jan 1, 2017

Latest May 7, 2026.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. R01

    Targeting the Hippo-YAP/TEAD Signaling Network in Head and Neck Cancer

    $695k

    May 7, 2026NCIUNIVERSITY OF CALIFORNIA, SAN DIEGONIH RePORTER · 11392048 (opens the source filing in a new tab)

  2. R01

    Targeting Systems Vulnerabilities in the EGFR/HER3/HER2 Oncogenic Signaling Circuitry: New Precision Therapies for Oral Cancer

    $483k

    Jul 1, 2025NIDCRUNIVERSITY OF CALIFORNIA, SAN DIEGONIH RePORTER · 11246910 (opens the source filing in a new tab)

  3. R01

    Targeting Systems Vulnerabilities in the EGFR/HER3/HER2 Oncogenic Signaling Circuitry: New Precision Therapies for Oral Cancer

    $486k

    Jul 1, 2025NIDCRUNIVERSITY OF CALIFORNIA, SAN DIEGONIH RePORTER · 11375190 (opens the source filing in a new tab)

  4. R01

    Reprogramming the Tumor Immune Microenvironment with Chemokines to Potentiate Immune Oncology Treatments in Oral Cancer

    $586k

    Mar 1, 2024NIDCRUNIVERSITY OF CALIFORNIA, SAN DIEGONIH RePORTER · 11042201 (opens the source filing in a new tab)

  5. R01

    Reprogramming the Tumor Immune Microenvironment with Chemokines to Potentiate Immune Oncology Treatments in Oral Cancer

    $575k

    Mar 1, 2024NIDCRUNIVERSITY OF CALIFORNIA, SAN DIEGONIH RePORTER · 11284019 (opens the source filing in a new tab)

  6. R01

    Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal Melanoma

    $522k

    Apr 1, 2021NCIUNIVERSITY OF CALIFORNIA, SAN DIEGONIH RePORTER · 11095748 (opens the source filing in a new tab)

  7. R01

    Targeting Signaling Vulnerabilities for Oral Cancer Prevention

    $475k

    Jan 1, 2017NIDCRUNIVERSITY OF CALIFORNIA, SAN DIEGONIH RePORTER · 11077779 (opens the source filing in a new tab)

  8. R01

    Targeting Signaling Vulnerabilities for Oral Cancer Prevention

    $475k

    Jan 1, 2017NIDCRUNIVERSITY OF CALIFORNIA, SAN DIEGONIH RePORTER · 11311828 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources